Hair loss drug showdown: which works better?
NCT ID NCT07190534
First seen Sep 30, 2025 · Last updated Jun 19, 2026 · Updated 31 times
Summary
This study compares two medicines, hydroxychloroquine and methotrexate, to see which works better for frontal fibrosing alopecia, a type of scarring hair loss that mainly affects women. About 50 adults who choose to start one of these treatments will be followed for up to 48 weeks. The goal is to measure how well each medicine controls disease activity and improves quality of life, helping doctors make better treatment recommendations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FRONTAL FIBROSING ALOPECIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Erasmus MC University Medical Center
Rotterdam, South Holland, 3015GD, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.